NICE recommends glofitamab for DLBCL
Published on: 18 October 2023New treatment available for relapsed or refractory diffuse large B-cell lymphoma.
The National Institute for Health and Care Excellence (NICE) has recommended glofitamab as an option for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in adults after 2 or more systemic therapies.
Glofitamab is a bispecific antibody, which is a new class of immunotherapy drug. Bispecific antibodies work by attaching to two targets, one on the surface of lymphoma cells and one on the surface of T cells (part of the immune system). This means that cells of the immune system come into direct contact with the lymphoma cells, and this leads to activation of the T-cells which in turn kill the lymphoma cells.
I am delighted that NICE have approved glofitamab for relapsed DLBCL, this offers a new treatment to patients who have not responded or relapsed after 2 or more previous treatments and in my experience it is usually well tolerated.
in the UK in 2018 as part of a clinical trial. Sandra achieved a
very good response and remains in remission 5 years later.
Look out for the Winter 2023 issue of our Lymphoma Matters magazine coming soon, where Dr William Townsend explains what bispecific antibodies are and how they can be used in the treatment of lymphoma. Sign-up to get future issues with the latest lymphoma news and stories.
Find out more about drug development, approval and funding, or visit Lymphoma TrialsLink for the latest on clinical trials for lymphoma.